Kennt denn niemand diese Aktie ? - 500 Beiträge pro Seite

[s97446]

Kennt denn niemand diese Aktie (VGIN, WKN 908848) ? Ich frage nur, da noch kein einziges Posting dazu zu finden ist ?

Der Wert wurde in BO 42/00 im Interview mit Kurt v. Emster (erfolgreicher Manager des Franklin-Biotechnologie-Discovery-Fonds) erwähnt. Lt. seiner Auskunft identifiziert man bei VGIN Viren maschinell, um exakt abgestimmte Medikamente zu wählen. So wäre theoretisch irgendwann einmal eine Art "individuelle Tablette" vorstellbar ...

Alles in allem finde ich den Wert interessant - wäre schön, wenn eine Diskussion zustande kommen würde ...

[cosmolina]

Hab´ was gefunden,klingt wirklich interessant, bin aber jetz zu müde für mehr:June 30, 1999
QIAGEN AND VISIBLE GENETICS INTEND TO ENTER INTO SUPPLY AGREEMENT FOR QIAAMP PRODUCTS

Hilden, Germany and Toronto, Canada, June 30, 1999 - QIAGEN GmbH, a wholly owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF, Frankfurt Neuer Market: QIA) and Visible Genetics Inc. (VGI) (Nasdaq:VGIN) today announced their intent to enter into a three-year supply agreement. Under the terms of the intended agreement, QIAGEN will supply VGI with certain proprietary nucleic acid sample preparation products from QIAGEN`s QIAamp™ product line. As announced by VGI on June 29, 1999, VGI intends to market such QIAamp products, in combination with a QIAGEN-developed extension for ultra-low level HIV genotyping, under the name TruPrep™ for use with VGI`s HIV TruGene™ HIV genotyping product. The TruPrep™ system components are clearly identified and marked as QIAGEN products.

QIAGEN and VGI have worked together closely over the last six months to develop an optimized nucleic acid extraction protocol for genotypic assays that can consistently obtain results below 100 copies of virus nucleic acid per milliliter of sample. The results of this successful collaboration were presented at the 3rd International Workshop on Drug Resistance and Treatment Outcomes in San Diego, California, held last week.

Viral resistance to HIV drugs originates from mutations resulting from low-level replication of HIV in patients under therapies where virus levels are suppressed. To facilitate efficient and effective treatment of HIV patients, these ultra-low viral loads must be monitored. Researchers have been trying to perfect a technique for ultra-low genotyping of viral nucleic acid samples because it would provide clinicians treating HIV-infected patients with at least two potential advantages. Clinicians may be able to correlate current treatments with existing resistance mutations reflected in nucleic acid patterns, and thereby confirm the maintenance of a patient`s drug regimen. At the same time, ultra-low level genotyping could alert clinicians to emerging resistance mutations of the virus` nucleic acid. This information could have the potential to allow them to adjust drug therapy before viral loads spiked out of control, before drugs failed, and before viruses developed so called cross-resistances which reduce treatment options.

VGI therefore believes that ultra-low level genotyping may have the potential to improve the treatment of HIV. With ultra-low level genotyping it may possible to preserve drug choice options even in patients with previously only very difficult to detect viral loads of less than 200 copies/ml. The QIAamp product solutions incorporated in VGI`s HIV TruGene product provide the ultra sensitive nucleic acid extraction tools required for nucleic acid detection and analysis on which such ultra-low level genotyping systems are based.

"We are excited about our new alliance with QIAGEN. QIAGEN is the consistent leader in DNA and RNA extraction technology and has built by far the most powerful and broad technology base in this field," said John K. Stevens Chairman and CEO of VGI. "In this partnership, we have found the strongest partner possible for the crucial step of nucleic acid sample preparation, for both today`s systems and our future needs. We expect to begin marketing of these products for use with our TruGene™ HIV Kit in Europe and the US later this year".

"This intended agreement with VGI is a further demonstration of the power of the technology of our QIAamp product line. QIAamp technology facilitates highly reliable and sensitive nucleic acid purification - a prereqisite for many applications in nucleic acid-based diagnostics such as the detection and analysis of infectious agents and monitoring gene-expression," said Helge Bastian, QIAGEN`s Business Unit Manager of Molecular Diagnostics. "In combination with QIAGEN`s BioRobot instrumentation technology, the QIAamp technology also opens a wide range of automated nucleic acid purification options. We expect QIAamp technology components to be integrated into a broad range of downstream applications and contribute to expanding our technology and market leadership in reliable and reproducible nucleic acid isolation and purification from biological samples."

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Australia and Canada, believes it is the world`s leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 280 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation and related services. QIAGEN`s products are sold in more than 42 countries throughout the world to academic research markets and also to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 830 people worldwide.

Visible Genetics Inc. manufactures and markets high performance automated DNA sequencing systems and complete kits for the analysis of genes linked to disease. The Company’s OpenGene* system employs proprietary stratified DNA testing and single-tube, single-step sequencing methods to significantly reduce the time and cost involved in identifying clinically relevant genetic information. VGI is a leader in the emerging field of pharmacogenomics which will use genetic information in the identification, and analysis of genes in order to improve patient care and reduce healthcare costs.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN`s products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN`s products (including seasonal fluctuations), difficulties in successfully adapting the Company`s products to integrated solutions and producing such products, and the Company`s ability to identify and develop new products and to differentiate its products from competitors. For further information, refer to the discussion in reports that the Company has filed with the U.S. Securities and Exchange Commission (SEC).


--------------------------------------------------------------------------------